A new gadolinium-based contrast agent, gadopiclenol, at clinical and supraclinical doses does not result in prolonged QT interval and has an acceptable safety profile among healthy volunteers, a recent study has found.
The use of angiotensin converting enzyme inhibitors (ACEIs) and angiotensin II type-1 receptor blockers (ARBs) seem to protect against confusion in patients of the novel coronavirus disease (COVID-19) with hypertension, a recent Japan study has found.
Overprescribing of opioids after ophthalmic surgery can be reduced without increasing refill rates by standardizing opioid prescribing guidelines and discussing postsurgical pain management, suggests a recent study. Continued education is also needed to improve adherence to the prescribing guidelines.
Dapagliflozin therapy with doses higher than 10 mg appears to deliver greater beneficial effects in haematocrit, systolic blood pressure, urinary albumin–creatinine ratio, and uric acid, with no evident increases in the rate of adverse events, a recent study has shown.
The combination of baricitinib plus corticosteroids appears to produce meaningful improvements in pulmonary function in patients with moderate to severe SARS-CoV-2 pneumonia compared with corticosteroids alone, as shown in a study.
Survival and clinical outcomes in patients with advanced stage endometrial cancer are comparable among the different sequences of adjuvant chemotherapy and radiation therapy, a recent study has shown. However, “sandwich” therapy results in less chronic toxicity, which provides an opportunity for a better quality of life in survivorship.
Among inflammatory bowel disease (IBD) patients with a current or prior malignancy, treatment with vedolizumab or antitumour necrosis factor (anti-TNF) does not bear an increased hazard of developing new or recurrent cancer, as shown in a study.
Treatment with E6011, a novel cell trafficking inhibitor targeting the fractalkine (FKN)‐CX3CR1 interaction, confers modest benefits in rheumatoid arthritis (RA), according to the results of a phase II trial.
Several strategies have been proposed to help manage the adverse events (AEs) that emerged during the BEACON CRC trial which assessed the effect of encorafenib plus cetuximab in patients with BRAF V600E mutant metastatic colorectal cancer (mCRC) who had progressed after one or two prior regimens.